Proteros biostructures GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. Enter into Protein Crystallography Agreement

MARTINSRIED, Germany & RIDGEFIELD, Conn.--(BUSINESS WIRE)--Proteros biostructures GmbH announced today that it has entered into a research collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. in the field of protein crystallography. Under the terms of the agreement, which will run for 18 months, Proteros will receive research funding fees and success payments for the generation and analyses of protein-ligand-structures of hits and evolved chemical entities from in-house Boehringer Ingelheim programs. Proteros will apply its proprietary Free Mounting System (FMSTM) and PicodropperTM technologies to maximize data quality and success rates, thus allowing rapid evolution of multiple hit series at Boehringer Ingelheim.